SCHEMBL18656937

SCHEMBL18656937

O=C1CC(=O)N(CC(F)c2ccccc2)C(=O)N1CCc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.70
▸ MEN1 O00255 5/20 0.70
▸ MAPT P10636 4/20 0.70
▸ GAA P10253 4/20 0.70
▸ HSD17B10 Q99714 2/20 0.70
▸ USP2 O75604 2/20 0.70
▸ HTT P42858 2/20 0.70
▸ L3MBTL1 Q9Y468 2/20 0.70
▸ ALDH1A1 P00352 6/20 0.50
▸ BLM P54132 2/20 0.50
▸ APAF1 O14727 1/20 0.50
▸ CASP1 P29466 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ CASP7 P55210 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ RECQL P46063 1/20 0.49
▸ GSK3A P49840 2/20 0.43
▸ GSK3B P49841 2/20 0.43
▸ MGLL Q99685 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10158844 0.89 KMT2A (0.49) KMT2AMEN1MAPTGAAHSD17B10
SCHEMBL10158875 0.89 KMT2A (0.49) KMT2AMEN1MAPTGAAHSD17B10
SCHEMBL10158862 0.89 KMT2A (0.49) KMT2AMEN1MAPTGAAHSD17B10
SCHEMBL18656956 0.89 KMT2A (0.49) KMT2AMEN1MAPTGAAHSD17B10
SCHEMBL10159473 0.89 KMT2A (0.49) KMT2AMEN1MAPTGAAHSD17B10
SCHEMBL18656913 0.84 KMT2A (0.51) KMT2AMEN1MAPTGAAHSD17B10
SCHEMBL10158776 0.84 KMT2A (1.00) KMT2AMEN1MAPTGAAHSD17B10
SCHEMBL10159405 0.84 KMT2A (0.70) KMT2AMEN1MAPTGAAHSD17B10
SCHEMBL18656955 0.83 MAPT (0.50) KMT2AMEN1MAPTGAAHSD17B10
SCHEMBL18656967 0.82 MAPT (0.49) KMT2AMEN1MAPTGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144299-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Cambria Pharmaceuticals, Inc. (US) 2017-03-22 — — EP disclosed
Send feedback